Trial Profile
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- Acronyms DAFNE
- Sponsors Astellas Pharma
- 01 Jun 2021 Results (n=294) assessing the characteristics, management and outcomes of hospitalised patients with clostridium difficile infection who were treated with fidaxomicin and also describes the management of patients with CDI who did not receive fidaxomicin, published in the Journal of International Medical Research.
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.